StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Avalo Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $64.35M, up 57.3% year over year. For fiscal 2025 it was $50.08M, up 105.0% from the year before. Over ten years it grew 22.5% a year on average. The highest annual figure on record is $59.84M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$50.08M+105.0%
FY2024Dec 31, 2024$24.44M+77.3%
FY2023Dec 31, 2023$13.78M-56.0%
FY2022Dec 31, 2022$31.31M-47.7%
FY2021Dec 31, 2021$59.84M+85.9%
FY2020Dec 31, 2020$32.19M+173.7%
FY2019Dec 31, 2019$11.76M+103.3%
FY2018Dec 31, 2018$5.79M+32.3%
FY2017Dec 31, 2017$4.37M-56.9%
FY2016Dec 31, 2016$10.15M+54.1%
FY2015Dec 31, 2015$6.59M-46.2%
FY2014Dec 31, 2014$12.24M+37.3%
FY2013Dec 31, 2013$8.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.42M+66.4%
Q1 FY2026Mar 31, 2026$14.05M+54.0%
Q4 FY2025Dec 31, 2025$13.27M+62.1%
Q3 FY2025Sep 30, 2025$13.62M+42.8%
Q2 FY2025Jun 30, 2025$14.07M+205.9%
Q1 FY2025Mar 31, 2025$9.12M+331.1%
Q4 FY2024Dec 31, 2024$8.18M+338.3%
Q3 FY2024Sep 30, 2024$9.54M+663.7%
Q2 FY2024Jun 30, 2024$4.60M-1.2%
Q1 FY2024Mar 31, 2024$2.12M-64.8%
Q4 FY2023Dec 31, 2023$1.87M-69.8%
Q3 FY2023Sep 30, 2023$1.25M-82.3%
Q2 FY2023Jun 30, 2023$4.66M-45.3%
Q1 FY2023Mar 31, 2023$6.01M-37.3%
Q4 FY2022Dec 31, 2022$6.17M-46.4%
Q3 FY2022Sep 30, 2022$7.04M-33.3%
Q2 FY2022Jun 30, 2022$8.51M-32.3%
Q1 FY2022Mar 31, 2022$9.58M-62.0%
Q4 FY2021Dec 31, 2021$11.51M-8.9%
Q3 FY2021Sep 30, 2021$10.55M+18.9%
Q2 FY2021Jun 30, 2021$12.57M+112.4%
Q1 FY2021Mar 31, 2021$25.21M+428.6%
Q4 FY2020Dec 31, 2020$12.64M+334.7%
Q3 FY2020Sep 30, 2020$8.87M+408.9%
Q2 FY2020Jun 30, 2020$5.92M+59.4%
Q1 FY2020Mar 31, 2020$4.77M+40.2%
Q4 FY2019Dec 31, 2019$2.91M+44.9%
Q3 FY2019Sep 30, 2019$1.74M+66.4%
Q2 FY2019Jun 30, 2019$3.71M+242.9%
Q1 FY2019Mar 31, 2019$3.40M+106.2%
Q4 FY2018Dec 31, 2018$2.01M+2.3%
Q3 FY2018Sep 30, 2018$1.05M+8.6%
Q2 FY2018Jun 30, 2018$1.08M+119.3%
Q1 FY2018Mar 31, 2018$1.65M+73.1%
Q4 FY2017Dec 31, 2017$1.96M+153.7%
Q3 FY2017Sep 30, 2017$964.57K-78.9%
Q2 FY2017Jun 30, 2017$493.65K–
Q1 FY2017Mar 31, 2017$953.07K–
Q4 FY2016Dec 31, 2016$773.00K–
Q3 FY2016Sep 30, 2016$4.58M–

More Avalo Therapeutics figures

See a number that looks wrong?